SAN CARLOS, Calif., Oct. 13, 2016
SAN CARLOS, Calif., Oct. 13, 2016 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present data from Horizon™ carrier screen and Spectrum® pre-implementation genetic screening (PGS) studies at the Annual Meeting of the American Society for Reproductive Medicine (ASRM) Conference in Salt Lake City on Oct. 15-19, 2016. The diverse set of data that will be presented at the conference includes a PGS study on the incidence of triploidy, an underdiagnosed embryo abnormality that is estimated to occur in one to three percent of pregnancies; as well as real-world data that provides important insights on Duchenne muscular dystrophy and makes a compelling case for broad-population carrier screening. Both studies underscore Natera's ongoing commitment to pioneering tests that offer, from pre-conception to delivery, comprehensive and highly accurate, next-generation genetic screening.
"As a leader in genetic screening, Natera is committed to translating our innovative science into tests that make a difference in the lives of patients," said Kimberly Martin, MD, FRCSC, FCCMG, FACOG, FASMG, Senior Global Medical Director, Women's Health at Natera. "The clinical and real-world data that we're presenting at ASRM also demonstrates our growing commitment to finding better risk assessment options for patients dealing with infertility and other reproductive challenges. We look forward to sharing our detailed PGS triploidy incidence data, along with data in support of broad population screening for Duchenne – both of which highlight the advances in reproductive testing that now provide women with more options than ever before to aid in their reproductive decision-making."
Conference attendees can visit Natera at Booth #1923 for more information about Natera's in vitro fertilization (IVF) product portfolio, which includes the Horizon™ carrier screen to determine if patients are carriers of specific recessive and X-linked conditions, the Spectrum® pre-implantation genetic tests for embryo selection during IVF; the Panorama® prenatal screen, which screens placental DNA to determine if the fetus could be at high risk for specific genetic disorders such as Down Syndrome, and the Anora® miscarriage test to understand the genetic causes of a pregnancy loss. Abstracts are available online.
Below is a list of the highlighted Natera presentations at ASRM:
Title: Triploidy: A critical yet under-diagnosed embryo abnormality: review of data from pre-implantation genetic screening via single nucleotide polymorphism microarrays with bioinformatics
Presenter:Katrina Merrion, MS, CGC; Certified Genetic Counselor; Senior Genetic Counselor Manager; Natera, Inc.
Date:Tuesday, October 18, 2016
Session number: PO01
Publication number: P-142
Title: Duchenne/Becker muscular dystrophy: advances in reproductive testing options
Presenter:Sheraden Mundy, Clinical Content Associate Manager; Natera, Inc.
Date:Wednesday, October 19, 2016
Session number: PO02
Publication number: P-706
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier test to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to detect for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Each test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test.
These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.
Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit http://www.natera.com and connect on Twitter and Facebook.
This release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements for any reason after the date of this press release.
These forward-looking statements are subject to a number of known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our ability to increase demand for our products and obtain favorable coverage and reimbursement determinations from third-party payers, our expectations of the reliability, accuracy, and performance of our products, or of the benefits of our products to patients, providers, and payers.
Additional risks and uncertainties are discussed in greater detail in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Natera's Form 10-Q for the period ended June 30, 2016. Further information on potential risks that could affect actual results will be included in other filings Natera makes with the SEC from time to time. These documents are available for free on the company's website at www.natera.com under the Investor Relations section, and on the SEC's website at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/natera-announces-two-poster-presentations-on-triploidy-and-duchenne-muscular-dystrophy-to-be-featured-at-the-2016-american-society-for-reproductive-medicine-asrm-conference-300344078.html
SOURCE Natera, Inc.PR Newswire
Last updated on: 13/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.